文献速递心脑血管急症消化、代谢与肾脏急症

前列腺癌退伍军人雄激素剥夺治疗后不良事件的种族差异

Racial Differences in Adverse Events After Androgen Deprivation in Veterans With Prostate Cancer.
PubMed 文献 · JAMA Netw Open · 2025-11-03
一句话结论在790 916例前列腺癌退伍军人中,雄激素剥夺治疗与心血管事件和骨相关不良事件风险升高相关,且各人种均存在此关联。

这项回顾性、全国性、基于人群的队列研究利用退伍军人事务医疗系统数据库2001年1月至2021年12月的数据,纳入790 916例前列腺癌退伍军人,评估雄激素剥夺治疗(ADT)与心血管及骨相关不良事件时间的关系。ADT与心血管事件(HR 1.16;95%CI 1.15-1.17;P<.001)、骨折(HR 1.59;95%CI 1.55-1.62;P<.001)、骨质疏松(HR 2.73;95%CI 2.65-2.80;P<.001)及复合事件(HR 1.29;95%CI 1.27-1.30;P<.001)风险升高相关。按种族分层后,ADT在所有种族中仍与所有结局显著相关。黑人患者与白人患者相比,ADT导致的超额风险在心血管事件(HR 1.09 vs 1.18)和骨折(HR 1.35 vs 1.65)上略低,但在骨质疏松上更高(HR 3.16 vs 2.64);西班牙裔和其他种族患者的HR与白人患者非常相似。作者认为这些发现强调需要对接受ADT的患者进行监测和缓解策略。

要点

  • 在790 916例前列腺癌退伍军人中,ADT与心血管事件风险升高相关(HR 1.16;95%CI 1.15-1.17;P<.001)。
  • ADT与骨折(HR 1.59;95%CI 1.55-1.62;P<.001)和骨质疏松(HR 2.73;95%CI 2.65-2.80;P<.001)风险升高相关。
  • 按种族分层后,ADT在所有种族中仍与所有结局显著相关。
  • 黑人患者ADT相关心血管事件HR 1.09(95%CI 1.06-1.17)vs 白人患者1.18(95%CI 1.16-1.19),骨折HR 1.35(95%CI 1.28-1.42)vs 1.65(95%CI 1.61-1.70),骨质疏松HR 3.16(95%CI 2.95-3.38)vs 2.64(95%CI 2.56-2.73)。
  • 作者认为这些发现强调需要对接受ADT的患者进行监测和缓解策略。

适用人群与场景

  • 纳入:前列腺癌退伍军人,使用退伍军人事务医疗系统数据库2001年1月至2021年12月的数据,随访至死亡或研究结束。
  • 排除:接受双侧睾丸切除术、接受促性腺激素释放激素拮抗剂治疗、或缺乏种族和民族数据的患者。

研究设计与关键结果

  • 研究类型:回顾性、全国性、基于人群的队列研究,样本量790 916例前列腺癌退伍军人(西班牙裔30 139例[4%];非西班牙裔黑人145 267例[18%];非西班牙裔白人598 574例[76%];其他种族16 936例[2%])。
  • 暴露:促黄体生成素释放激素激动剂(亮丙瑞林、戈舍瑞林或曲普瑞林)作为时间依赖变量和一线全身治疗。
  • 主要终点:ADT与心血管事件风险升高相关(HR 1.16;95%CI 1.15-1.17;P<.001)。
  • 次要终点:ADT与骨折(HR 1.59;95%CI 1.55-1.62;P<.001)、骨质疏松(HR 2.73;95%CI 2.65-2.80;P<.001)和复合事件(HR 1.29;95%CI 1.27-1.30;P<.001)风险升高相关。
  • 按种族分层:ADT在所有种族中仍与所有结局显著相关;黑人患者 vs 白人患者,心血管事件HR 1.09(95%CI 1.06-1.17)vs 1.18(95%CI 1.16-1.19),骨折HR 1.35(95%CI 1.28-1.42)vs 1.65(95%CI 1.61-1.70),骨质疏松HR 3.16(95%CI 2.95-3.38)vs 2.64(95%CI 2.56-2.73);西班牙裔和其他种族患者的HR与白人患者非常相似。

证据类型、等级与局限

  • 证据类型:回顾性、全国性、基于人群的队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为这些发现强调需要对接受ADT的前列腺癌患者进行监测和缓解策略。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Androgen deprivation therapy (ADT) for prostate cancer (PC) has been linked to adverse events, such as cardiac events and osteoporosis. Whether these associations differ by race is unknown.

OBJECTIVE: To assess the association between ADT and time to cardiovascular and bone-related adverse events across racial groups.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective, nationwide, population-based, cohort study used electronic health records from the Veterans Affairs Health Care System (VAHCS) database from January 2001 to December 2021, with follow-up until death or study end. Participants included veterans with PC. Patients undergoing bilateral orchiectomy, receiving gonadotropin-releasing hormone antagonists, or lacking data on race and ethnicity were excluded. Data analysis was performed from January to March 2023.

EXPOSURE: Luteinizing hormone-releasing hormone agonists (leuprolide, goserelin, or triptorelin) use as a time-dependent variable and first-line systemic therapy.

MAIN OUTCOMES AND MEASURES: The primary outcome was time to first cardiovascular event (myocardial infarction, stroke, coronary heart disease, congestive heart failure, or peripheral vascular disease). Secondary outcomes included osteoporosis, bone fracture, and a composite event (any of these). Cox models assessed the association between ADT as a time-dependent covariate and time-to-event across all patients by race.

RESULTS: Among 790 916 veterans with PC (30 139 [4%] Hispanic; 145 267 non-Hispanic Black [18%]; 598 574 non-Hispanic White [76%]; and , 16 936 other races [2%]), ADT was associated with increased risk of cardiovascular events (hazard ratio [HR], 1.16; 95% CI, 1.15-1.17; P < .001), bone fractures (HR, 1.59; 95% CI, 1.55-1.62; P < .001), osteoporosis (HR, 2.73; 95% CI, 2.65-2.80; P < .001), and composite event (HR, 1.29; 95% CI, 1.27-1.30; P < .001). When stratified by race, ADT remained significantly associated with all outcomes among all races. Among Black patients, compared with White patients, the excess risk due to ADT was slightly lower for cardiovascular events (HR, 1.09 [95% CI, 1.06-1.17] vs 1.18 [95% CI, 1.16-1.19]) and bone fracture (HR, 1.35 [95% CI, 1.28-1.42] vs 1.65 [95% CI, 1.61-1.70]) but higher for osteoporosis (HR, 3.16 [95% CI, 2.95-3.38] vs 2.64 [95% CI, 2.56-2.73]). HRs for Hispanic patients and those of other races were very similar to those for White patients.

CONCLUSIONS AND RELEVANCE: In this cohort study of 790 916 veterans with PC, ADT was associated with increased cardiovascular and bone risks across all racial groups. Although excess risks differed slightly between Black and White patients, overall differences were small. These findings highlight the need for monitoring and mitigation strategies for patients receiving ADT.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Friedrich NA, Janes JL, Parrish J, et al. Racial Differences in Adverse Events After Androgen Deprivation in Veterans With Prostate Cancer. JAMA Netw Open. 2025. PMID: 41259022. doi:10.1001/jamanetworkopen.2025.45705

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。